Vincent M Balanag Selected Research

Aftercare (After-Treatment)

3/2023

Treatment Strategy for Rifampin-Susceptible Tuberculosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vincent M Balanag Research Topics

Disease

2	Tuberculosis (Tuberculoses) 07/2023 - 03/2023
2	Pulmonary Tuberculosis 07/2023 - 03/2023
1	Chronic Obstructive Pulmonary Disease (COPD) 10/2011
1	Obstructive Lung Diseases (Obstructive Lung Disease) 10/2011

Drug/Important Bio-Agent (IBA)

2	Ethambutol (Myambutol)FDA LinkGeneric 07/2023 - 03/2023
2	Isoniazid (Ftivazide)FDA LinkGeneric 07/2023 - 03/2023
2	Pyrazinamide FDA LinkGeneric 07/2023 - 03/2023
2	Rifampin (Rifampicin)FDA LinkGeneric 07/2023 - 03/2023
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2023
1	Rosuvastatin Calcium (Crestor)FDA Link 07/2023
1	Linezolid (Zyvox)FDA Link 03/2023
1	bedaquiline (R207910)IBA 03/2023
1	Bronchodilator Agents (Bronchodilators)IBA 10/2011
1	GoldIBA 10/2011

Therapy/Procedure

1	Therapeutics 07/2023
1	Retreatment 03/2023
1	Aftercare (After-Treatment) 03/2023
1	BOLD protocol 10/2011